The Madison-area Usona Institute has landed on a very short federal shortlist, winning fast-track status to study psilocybin as a treatment for major depression after an April 18 executive order vaulted certain psychedelic drugs onto a national priority list. The award hands Usona a special review voucher meant to speed up Food and Drug Administration timelines and puts the nonprofit in a three-team club selected for accelerated scrutiny. Local researchers say the nod validates years of work, even as it raises thorny questions about how and where any future treatments would actually reach patients. Officials and scientists stress that the voucher can speed the regulatory calendar but does not loosen the evidence standards that FDA will use to judge the data. White House materials frame the move as a response to stubbornly high suicide rates and treatment-resistant mental health conditions, particularly among veterans. Industry watchers say the trio, which includes two psilocybin efforts and one methylone program, is a sign of how quickly late-stage psychedelic research has moved from fringe concept to potential approval track. The Usona Institute is listed as the sponsor of a Phase 3 trial of psilocybin for major depressive disorder on ClinicalTrials.gov, a signal that the nonprofit is already working near the end of the traditional testing pipeline. The executive order instructs agencies to develop plans for handling, access and rescheduling as trials move forward, according to the White House. Usona described itself as “deeply grateful” for the selection in comments reported by Urban Milwaukee, and UW–Madison researchers say they are preparing training pipelines in case regulators clear these therapies. The voucher may be a jump-start for Madison’s mushroom research, but whether the broader health system can keep pace is the part no one can fast-track. According to Wisconsin Public Radio, the voucher comes through a new federal pilot program that aims to shrink what is often six to ten months of FDA review down to roughly one to two months for qualifying applications.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://hoodline.com/2026/05/feds-hand-madison-mushroom-lab-a-golden-ticket-in-depression-drug-race/